EU MDR clinical evaluation Article 61 and Annex XIV overview

Article 61 ties clinical evaluation directly to MDR Annex I. The evaluation must use sufficient clinical evidence to confirm conformity with relevant general safety and performance requirements, assess undesirable side-effects, and support the acceptability of the benefit-risk ratio under normal intended use.

Annex XIV turns that obligation into a method: plan the evaluation, identify which GSPRs need clinical data, search for available clinical data and evidence gaps, appraise the data, generate additional data when needed, and analyse the evidence into conclusions on safety, clinical performance, and clinical benefits.

For implantable and class III devices, Article 61(4) generally requires clinical investigations unless a specific Article 61(4)-(6) route applies. Those routes have separate conditions; prior marketing, a familiar product type, or an equivalence claim does not by itself remove the investigation requirement.

MDR clinical data can come from clinical investigations of the device, clinical investigations or other studies reported in scientific literature for an equivalent device, peer-reviewed literature on clinical experience with the device or an equivalent device, and clinically relevant PMS information including PMCF.

Equivalence has strict conditions. Annex XIV requires technical, biological, and clinical characteristics to be considered, and MDCG 2020-5 stresses that differences must be identified, scientifically justified, and shown not to create clinically significant differences in safety or clinical performance.

Article 61 requires the clinical evaluation, its results, and the clinical evidence derived from it to be documented in a clinical evaluation report. Except for custom-made devices, that report is part of the technical documentation for the device.

A useful CER connects the clinical evaluation plan, literature search and appraisal, investigations, equivalence rationale if used, PMS and PMCF outputs, state of the art, IFU and claims, risk management, GSPR support, limitations, and benefit-risk conclusion.

Article 61(10), without overriding the investigation requirements in Article 61(4) for implantable and class III devices, permits reliance on non-clinical testing alone only when the manufacturer can justify that approach from risk management, the device's interaction with the human body, intended clinical performance, and claims. The technical documentation must contain the justification, and the clinical-evaluation duty still applies.

PMCF is part of the clinical evaluation lifecycle. Annex XIV describes PMCF as the continuous process that updates the clinical evaluation, and the PMCF plan must be addressed in the manufacturer's PMS plan.

PMCF should proactively collect and evaluate clinical data from the use of the CE-marked device within its intended purpose. The results feed the PMCF evaluation report, the CER, technical documentation, risk management, and benefit-risk reassessment. Annex II and Annex III allow a documented justification when PMCF is not applicable, but a silent omission or a statement that the device is already CE marked is not that justification.

Where a notified body assesses the device, clinical evaluation is a core review area. Annex VII and conformity assessment annexes require notified bodies to review clinical evidence, challenge equivalence where claimed, verify GSPR conclusions, consider risk management, IFU, user training, PMS, PMCF adequacy, and decide whether milestones are needed for post-certification clinical evidence updates.

For class III implantable devices and class IIb active devices intended to administer or remove a medicinal product, Article 54 adds a clinical evaluation consultation procedure unless an Article 54(2) exception applies. Exceptions cover specified certificate renewals, certain modifications of a device already marketed by the same manufacturer for the same intended purpose, and device types whose clinical-evaluation principles are addressed by a common specification and whose evaluation complies with it. The notified body's clinical evaluation assessment report documents the manufacturer's clinical evidence, benefit-risk determination, consistency with intended purpose and medical indications, and PMCF plan.